<DOC>
	<DOC>NCT00191269</DOC>
	<brief_summary>To investigate efficacy, safety and PK of GEM monotherapy after prior chemotherapy with anthracycline and taxane regimen for patients with metastatic breast cancer</brief_summary>
	<brief_title>Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Histologically and/or cytologically confirmed breast cancer Received prior chemotherapy for metastatic breast cancer with anthracycline and taxane regimen To have at least one measurable region PS: 01 To have adequate organ function (bone marrow, liver and renal function) To have Interstitial pneumonia or pulmonary fibrosis To have inflammatory carcinoma Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery To have brain metastasis with symptom To have severe complication (cardiac infarction, infection, drug hyper sensitivity or diabetes)</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>after</keyword>
	<keyword>anthracycline</keyword>
	<keyword>taxane</keyword>
	<keyword>regimen</keyword>
</DOC>